Amit Gupta, MD, discussed a new collaboration between University Hospitals Cleveland Medical Center and Qure.ai that aims to ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell ...

Regarding myeloma, Burke also shares his experience with myeloma BsAbs, saying, “I follow the drug label, administer the drug in the clinic, but then admit the patient directly to the hospital for ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Monzr M. Al Malki, MD, discussed data for AlloHeme, a blood test used to detect risk of relapse post-transplant in patients ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

For those that may not have the opportunity to be part of a clinical trial, Burke proceeds with a step-by-step process. Burke emphasizes that the first practical step is to educate oneself on the ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Panelists discuss second-line treatment options and emerging approaches for HER2-mutated non–-small cell lung cancer (NSCLC), highlighting novel therapies and clinical strategies.

During a live event, Payal D. Shah, MD, discusses the case of a woman with metastatic breast cancer and the data for ...

Yelena Y. Janjigian, MD, discusses the standard approval of pembrolizumab plus trastuzumab and chemotherapy for the treatment ...